Personalized Therapy of Lung Cancer 2011 Winter Lung Cancer Conference Thomas J. Lynch, Jr., M.D....
-
Upload
roderick-turner -
Category
Documents
-
view
221 -
download
0
Transcript of Personalized Therapy of Lung Cancer 2011 Winter Lung Cancer Conference Thomas J. Lynch, Jr., M.D....
Personalized Therapy of Lung Cancer
2011 Winter Lung Cancer Conference
Thomas J. Lynch, Jr., M.D.Jonathan and Richard Sackler Professor of Internal Medicine
Director, Yale Cancer CenterPhysician-in-Chief, Smilow Cancer Hospital
Lung Cancer 2011
• USA– 190,000 cases of lung cancer– 165,000 deaths– 165,300 cases of NSCLC– 115,000 cases of adenocarcinoma– 28,500 cases of lung cancer in never smokers
• Global– 1.4 million deaths from lung cancer
NCI SEER Cancer Statistics, WHO Fact Sheet.
Cancer 2011• Cancer is a disease caused by abnormal
genes that “drive” either excessive cell growth or inadequate cell destruction
• Imbalance of growth and death signals leads to growth of cancer cells into tumors
• Tumors then proceed to grow and metastasize
• Understanding which genes drive which cancers will provide a “roadmap” to curing cancer
Major Classes of Genomic Alterations that Give Rise to Cancer
• Point mutations• Copy number alterations
Deletions Amplifications
• Translocations Examples: BCR-ABL, EML4, ALK
MacConall LE and Garraway LA. J Clin Oncol 2010;28:5219-28.
Kate’s Story
• March 2002: Shortness of breath• April 2002: Lung cancer in brain, lung and
lymph nodes• Summer 2002: Chemotherapy• November 2002: Progression in liver
Kate November 2002 Pre Rx
Kate April 2003
Giaccone G et al. J Clin Oncol 2004;22:777-84. Herbst RS et al. J Clin Oncol 2004;22:785-94.
INTACT Trials: 1-Year Overall Survival
INTACT 1
• Gefitinib 500 mg + gemcitabine/cisplatin, 9.9 months
• Gefitinib 250 mg + gemcitabine/cisplatin, 9.9 months
• Placebo, 11.1 months
INTACT 2
• Gefitinib 500 mg + paclitaxel/carboplatin, 8.7 months
• Gefitinib 250 mg + paclitaxel/carboplatin, 9.8 months
• Placebo, 9.9 months
Sequist LV et al. J Clin Oncol 2008;26(15):2442-9.
First-Line Gefitinib in Patients with Advanced NSCLC Harboring
Somatic EGFR Mutations
• Mutations detected in 34/98 patients who underwent direct DNA sequencing of tumor tissue EGFR exons 18 to 21
– In-frame deletions of 11-15 bp, 53%
– L858R, 26%
– Atypical, 21%
• Objective response rate, 55%
• Median progression-free survival, 9.2 months
Resistance
There are 2 robustly described TKI-resistance mechanisms: T790M in EGFR and MET amplification
1 patient with both T790M and L858R had a best response of SD and remained on treatment for 55 days
Source: Sequist LV et al. Proc ASCO 2007. Abstract 7504
T790M
• Gatekeeper mutation present in nearly 60% of acquired resistance
• Rare familial germline mutations found• Detected at diagnosis in CTCs and circulating
DNA in 30% of patients using highly sensitive methods
• Efforts to target T790M are emerging
T790M
• Irreversible Dual (EGFR, Her-2) kinases have not yet proven effective in this setting
• Novel T790M specific inhibitor (Nathanael Gray-DFCI) under development
• Combination therapy might hold best hope
Adeno
Squam
Large
Small
KRAS
Unknown
EGFRHER2
BRAFALK fusion
PIK3CAMEK1
ROS fusionPDGFR amp
2011: Lung Adenoca-Multiple Molecular Subsets
Courtesy William Pao
Adeno
Squam
Large
Small
KRAS
Unknown
EGFR
HER2
ALK fusion
2011: Never Smoker Lung Adenoca (US)-Almost All Molecular Subsets Defined!
Pham D et al. J Clin Oncol 2006;24(11):1700.Stephens P et al. Nature 2004;431(7008):525.Shaw AT et al. J Clin Oncol 2009;27(26):4247.Riely GJ et al. Clin Cancer Res 2008;14(18):5731.
Somatic Mutations Affect Key Pathways in Lung Adenocarcinoma
• Discovery of more than 1,000 somatic mutations after sequencing 623 genes with known or potential relationships to cancer
• Identified 26/623 genes that are mutated at a significantly high frequency
– Most frequent: TP53, KRAS, STK11, EGFR
– Less frequent: LRP1B, KDR, RB1, LTK, SLC38A3, NRAS
• Genetic alterations frequently occur in genes of the MAPK, p53, Wnt and mTOR pathways
Ding L et al. Nature 2008;455:1069-75.
McDermott U et al. N Engl J Med 2011;364:340-50.
Tumor Tissue Heterogeneity and MicrodissectionTumor Tissue Heterogeneity and Microdissection
A.A. H&E micrographH&E micrographof prostate carcinoma of prostate carcinoma showing epithelial tissue showing epithelial tissue (red arrows) and stroma(red arrows) and stroma(black arrow).(black arrow).
B.B. Area of epithelial Area of epithelial tissue to be dissected out-tissue to be dissected out-lined by etching with lined by etching with laser.laser.
C.C. Tissue section afterTissue section afterremoval of outlined tissue.removal of outlined tissue.
D. Removed tissue.D. Removed tissue.
EGFREGFR mutation assay on normal mutation assay on normal tonsil DNAtonsil DNA
EGFREGFR mutation assay on DNA of a mutation assay on DNA of a formalin-fixed, paraffin-embedded formalin-fixed, paraffin-embedded sample of lung tumor with a sample of lung tumor with a heterozygous mutationheterozygous mutation
EGFR G719A, G719S, G719CE746_A750del, E746_S752>VL747_T751, L747_P753>ST790ML858RL861Q
KRAS G12S, G12R, G12D, G12V,G12C, G12AG13C, G13S, G13R, G13DQ61K, Q61L, Q61R, Q61H
BRAF V600E, V600K
NRAS G12C, G12S, G12R, G12D,G12V, G12AG13R, G13C, G13V, G13D,G13AQ61K, Q61L, Q61R, Q61H,Q61P
PIK3CA R88QE542KE545K, E545A, E545GQ546K, Q546RH1047Y, H1047L, H1047RG1049S, G1049R
PTEN R130*R173CR233*K267fs*
11
14
17
4
12
2
Gene Mutations tested Cancer type Targeted therapy
Total = 60 mutations
Lung (26%) TKIs: erlotinib, gefitinib (adenocarcinoma)
Lung (17%), colon (15%) Erlotinib, gefitinib;pancreas, biliary tract, cetuximabendometrium, ovary
Melanoma (50%), thyroid, PLX4032,biliary tract, colon (12%) GSK2118436
Melanoma (15%), Drugs targetingleukemia, colon (3%) RAS/RAF/MEK pathway
Breast, urinary tract, Drugs targetingendometrium, colon (13%), PI3K/AKT/mTORstomach, melanoma (5%) pathway
Endometrium, brain,prostate, colon (10%),melanoma (10-30%)
Genome Statistics
• 29,000 human genes
• Average gene 3000 bases but wide variation exists
• 99.9% of our bases are exactly the same from person to person
• Functions are unknown for 50% of the discovered genes
Progress in Sequencing the Human Genome• 2000
– 12 years– 1,800,000,000 USD
• 2010– 12 days– 20,000 USD
• 2011– 5 days– 5,000 USD
Yale Genome Statistics
• Human genome 3.2 billion bases or 3.2 Gbases
• Sept 2010 Yale sequences 1.8 trillion bases or 1800 Gbases
• In September Yale sequenced the equivalent of 562 human genomes!
• In January Yale sequenced 1300 human genomes!
Post Genome World• 2008 - EGFR and Ras mutation testing
routine• 2009 - Molecular genotyping - snapshot• 2010 - Whole genome sequencing begins
experimentally• 2012 - Routine WGS available to patients
Will we be ready?